GHRH (1–29) · Geref (historical)
Sermorelin
Historical label Cited compounding use
What it is
Sermorelin is GHRH 1–29, the shortest fragment that retains full GHRH activity. It had a US product history for diagnostic and pediatric GH-deficiency use; that branded product is gone. Compounded sermorelin still appears in clinic catalogs.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- A classic GHRH 1-29 analog used for years in US compounding / diagnostic GH testing.
- Same idea as CJC-no-DAC: ask the pituitary for a GH pulse, then go to sleep.
- Often the “first secretagogue” in clinic write-ups because it is the old familiar name.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Pituitary GHRH-receptor agonism with a short pulse, typically timed to the night-time GH window in secondary protocols.
Possible side effects / caveats
Flushing, headache, injection-site irritation, hypertonia in older labels, and the usual GH-axis caveats. Not a substitute for recombinant GH where GH is actually indicated.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited range | 200–300 mcg | Once daily, often evening | Common compounding-clinic figure |
| Cited range | 100–500 mcg | Daily | Wider secondary window |